How to Get the Best Results from Weight Loss Injections

What the trial results actually tell us about realistic outcomes

The headline figures from SURMOUNT-1 and STEP 1 (published in the New England Journal of Medicine) are genuine, but they come with context worth reading. Participants in both trials attended regular behavioural support sessions, followed structured reduced-calorie diets and increased their activity levels throughout. The medicine reduced appetite and slowed gastric emptying; the lifestyle changes gave the body somewhere useful to go with that reduced intake. Neither element worked as well without the other.

SURMOUNT-5 (2025) compared tirzepatide directly against semaglutide 2.4mg in a head-to-head trial of 751 adults with obesity and no diabetes over 72 weeks. Tirzepatide produced greater average weight reduction. That difference exists partly because tirzepatide activates two gut-hormone receptors (GIP and GLP-1) rather than one, the mechanism is described clearly on the weight loss injection overview. Whether that gap in average results translates to your individual outcome depends on your health history, your starting point and your tolerability of each medicine. It is a clinical question, not a ranking exercise.

One practical implication of the data: results accumulate over months, not weeks. The first pen is a tolerability dose, the body adjusts, appetite shifts gradually, and the bigger effects tend to emerge as the dose titrates upward. Expecting dramatic change in week two sets up unnecessary disappointment.

Consistency is the single biggest modifiable factor

A question our prescribers hear regularly: does it matter which day of the week you inject? The honest answer is less than people expect, provided the day stays the same. Consistent weekly spacing keeps drug levels stable. Pick a day you can reliably stick to, some patients find a Monday works because the week feels structured; others anchor it to payday or a standing diary reminder. The specific day is far less important than not drifting.

Missed injections are the most common reason outcomes fall short of trial averages. NHS guidance on semaglutide advises taking a missed dose as soon as possible within a defined window, after that, skip and resume the usual schedule. For tirzepatide, the same principle applies per the patient information leaflet. Never double-dose to compensate. If you are unsure, the right call is to contact your prescribing team rather than guess.

For a broader comparison of how the two main options differ in practice, the guide to choosing between weight loss injections sets out the key clinical distinctions.

Nutrition and activity: what the evidence supports during treatment

Appetite suppression from GLP-1 medicines is powerful enough that some people eat very little, and that is not automatically a good thing. Eating too little protein accelerates muscle loss alongside fat loss, which harms long-term metabolic health and makes weight maintenance harder after treatment ends. Clinical guidance consistently points to adequate protein at each meal (poultry, fish, eggs, pulses, dairy), regular hydration and fibre-rich foods to support gut comfort.

Resistance exercise (anything that asks muscles to work against load, from weights to bodyweight movements) has good evidence for preserving lean mass during significant calorie deficits. It does not need to be intense. Consistent, moderate effort over months beats occasional bursts. NICE's appraisal of tirzepatide (TA1026) frames these medicines as one part of a broader weight management approach, not a standalone fix.

GI side effects (nausea, bloating, loose stools) are most common after starting or after a dose step up. Eating smaller, lower-fat meals and slowing the pace of eating eases them for most people. If side effects are affecting your ability to eat or drink, tell your prescribing team, the titration pace can sometimes be adjusted.

If you want a personalised sense of which medicine and approach might suit your situation, the medicine-matching page walks through the clinical factors.

How clinical oversight shapes long-term success

The gap between trial-average results and real-world outcomes is partly a supervision gap. In trials, participants are monitored closely, doses are adjusted based on response, and side effects are managed proactively. In less-supervised private settings, people sometimes stay on a starter dose for months without escalation, or discontinue early because nausea felt unmanageable when a simple adjustment would have helped.

Regular clinical review matters. At nume, every weight loss injection repeat order is reviewed by a GPhC-registered Independent Prescriber before dispatch, a real clinician reads your update, not software. That review checks whether the current dose is still appropriate, whether any new symptoms need attention, and whether the plan is working. If you are considering starting treatment and want to understand the access process, the guide to getting weight loss injections covers the route from consultation to delivery.

You can also read about what realistic result timelines look like based on the clinical evidence, which can help set expectations before treatment begins. For anything specific to your circumstances, speaking to our prescribers directly is the most useful step. Start a free consultation and a prescriber will review your case the same day.